The drug, combined with Celgene's Vidaza, Otsuka's Dacogen or low-dose cytarabine, showed strong response rates in elderly and unfit AML patients, historically a hard-to-treat population.
The data for AMG 420 are early, an Amgen executive said, but where to place the drug relative to CAR-Ts is a "million-dollar question."
Choosing the right brain injury rehabilitation program is a critical decision that can shape the future for you or your loved one.
The company's adoptive cell therapy produced responses in central nervous system PTLD, a frequently lethal complication of stem cell and solid organ transplants.
The company presented Phase I data from its study of allogeneic CAR-T UCART19, as well as preclinical data on a BCMA CAR-T for multiple myeloma.
A company analysis deemed the patient's myelodysplastic syndrome was unrelated to LentiGlobin, but a news report indicated it may have stemmed from the conditioning regimen used in the trial.
Bispecific antibodies like Amgen's AMG 420 could present some competition to CAR-Ts. But could sequential use of the therapies - which target the same antigen - be possible?
Healthcare in the U.S. today exists in a complex, fragmented and costly system, and the people this system is designed for deserve a holistic approach to best address their individual health needs.
After its shares plunged nearly 50 percent in October, Alnylam, the double-stranded RNAi company, is trying to resurrect itself with new data at the annual meeting of the American Society of Hematology (ASH).